SOURCE: Market Pulse

February 16, 2006 08:30 ET

Market Pulse Breaking News Alert for Thursday, Feb. 16, 2006: DNAG -- South Louisiana Serial Killer Workshop to Be Presented at the American Academy of Forensics Science (AAFS) Annual Meeting on

February 20, 2006 in Seattle, Washington!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse.

ATLANTA, GA -- (MARKET WIRE) -- February 16, 2006 -- Market Pulse News Alert for this AM, Stocks to Watch are: DNAPrint Genomics, Inc. (OTC BB: DNAG), eOn Communications Corp. (NASDAQ: EONC), Amgen Inc. (NASDAQ: AMGN) and Applied Materials, Inc. (NASDAQ: AMAT).

Investors need to be watching DNAPrint Genomics, Inc. (OTC BB: DNAG) this AM! DNAPrint is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology, and consumer genetic tests. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWitness™, RETINOME™ (a predictive test for inferring eye color from a DNA sample), ANCESTRYbyDNA™, and EURO-DNA™. DNAPrint's management sees exciting growth opportunity in these markets to introduce and sell their novel products and services. DNAG just had excellent news out in a press release before Thursday's opening bell announcing that Dr. Matthew Thomas, Senior Scientist, is a scheduled speaker at the South Louisiana Serial Killer Workshop at the AAFS Annual Meeting on February 20, 2006 in Seattle, Washington! This could be great news for investors!

DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that Dr. Matthew Thomas, Senior Scientist, is a scheduled speaker at the South Louisiana Serial Killer Workshop at the AAFS Annual Meeting on February 20, 2006 in Seattle, Washington. Dr. Thomas will explain DNAPrint Genomics' role in focusing investigation efforts towards the correct suspect, Derrick Todd Lee, in the South Louisiana Serial Killer case. Dr. Thomas's presentation will explain the science behind the DNAWitness™ product and demonstrate the process that resulted in test results reflecting Derrick Todd Lee's 85% Sub-Saharan African ancestry. This information was instrumental in focusing investigation efforts on appropriate suspects. The refocused investigation resulted in an arrest less than two months after DNAPrint Genomics provided the information and the suspect was ultimately convicted.

The American Academy of Forensic Sciences is one of the world's largest and most renowned organizations of forensic scientists, with nearly 6,000 members in 57 countries. The annual meeting involves presentation of scientific papers and workshops designed to keep forensic scientists on the cutting edge of solving crime. One such workshop at this year's meeting involves a very complex, multifaceted investigation, which culminated in the apprehension and conviction of a serial killer. The experts involved in the case, including an investigator, several scientists, the profiler and legal experts, will come together to share their expertise and learning experiences, in the hopes of educating attendees so they can solve similar crimes more efficiently in their home jurisdictions.

In 2002 and 2003, murders of six victims were linked to a single assailant in Southern Louisiana. Multiple agencies were involved in the investigation and eventual prosecution of the cases, culminating in the death penalty sentence of Derrick Todd Lee in 2004. The hunt for the serial killer generated considerable media coverage, and resulted in wide sweeping effects to policy, legislation and funding. A variety of approaches were taken in the forensic investigation and prosecution of the crimes, including a blending of new technologies and trusted older techniques. The investigative use of databases generated unique leads when applied to the field of physical matching and comparison. A variety of DNA analytical methods, techniques, and applications were employed to link crimes together, eliminate suspects, implicate Lee, and bring novel investigative information to the serial killer task force, including ancestry determination which demonstrated that he was 85% African.

"The successful outcome of the Louisiana Serial Killer case in 2003 was a milestone for our DNAWitness forensic technology and brought nationwide attention to DNAPrint's capabilities in helping to solve complex crimes," stated President and Chief Executive Officer Richard Gabriel. "Since that time, DNAWitness or Retinome™ technologies are currently being utilized in more than 100 cases worldwide. Retinome™ provides an accurate inference of iris (eye) color from the measurement of proprietary single nucleotide polymorphisms (SNPs) distributed throughout the human genome and is a further advancement of DNAWitness technology. We are proud of our role in this investigation and we believe that there are many cases that would benefit from the application of our forensic technologies."

The forensic community will benefit by learning the keys to success, and avoiding the pitfalls, in large, multidiscipline, multiple murder investigations. Techniques learned will be immediately employable by forensic scientists, investigators and administrators in their own jurisdictions and casework. The forensic community and society as a whole will benefit through protection of individuals' rights by rapid exoneration of innocent suspects, the increased public safety resulting from early apprehension of serial predators, and the reduced-cost benefit of an effective investigation using the latest technology.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. ( is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Stocks in the news and acting well as of late include: eOn Communications Corp. (NASDAQ: EONC), Amgen Inc. (NASDAQ: AMGN) and Applied Materials, Inc. (NASDAQ: AMAT).

Information contained herein is the opinion of ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated one hundred fifty thousand dollars from DNAPrint Genomics, Inc. MP was also compensated four million restricted shares of common stock directly from DNAPrint Genomics, Inc. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Contact Information